It might be your grandfather. It might be your favorite aunt. It might be your next door neighbor.
You’re watching them struggle with pain day in and day out, and your hands are tied.
You care.
You’ve tried to help.
What if there was a better way?
And what if there was something you could do to fight the impersonal system and help your grandmother live pain free?
ElectroGear Wellness Product Line for sports performance and recovery
Our first product line is called ElectroGear, a wearable bioelectric device to personalize performance and recovery for
athletes and the rest of us.
The ElectroGear system includes:
We are combining 3 technologies to build something uniquely special.
We want to make pain management
Healables products integrate microcurrent technology. Microcurrent has been studied to enhance cell function in over 175 published papers. The goal of this CrowdFunding campaign is to bring this technology to you.
Invest in Healables to help us create personalized bioelectric wearables
– Dr. Andrew David Shiller, Harvard trained pain rehab specialist
Pain Relief In 64 users
The Healables system shows potential to Address Musculoskeletal issues
During user testing of the device, users reported improvements in Musculoskeletal conditions and relief in Musculoskeletal pain issues. These include the elbow, forearm, wrist, hand, knee, shoulder or upper or lower back.
During user testing of the device, users reported improvements in Inflammatory conditions and relief in Inflammatory pain issues. These include Fibromyalgia, Diabetic Neuropathy, Migraine, Respiratory and COPD.
And we feel that’s a good reason to invest in Healables.
Recovery in 1 day instead of 4
Sports Recovery Time without using ElectroGear
Invest in Healables to put AI at the center of pain management
Join us in our mission to continue fighting the impersonal health system.
Your investment may help more people access pain relief that targets the root — not the symptom.
The goal of the device is to:
Other industries and verticals
Help us get these products to more people
Olympic Athlete Training Institute “Wingate” is piloting the product, starting with their swimmers.
Healables is a proud graduate of the Intel Ignite accelerator, the Hadassah accelerator powered by IBM Alpha Zone and the Mass Challenge accelerator.
Leading automotive companies from German and Korea have each signed an NDA to explore integration of Healables tech in their vehicles.
Sheba Medical Center (one of the top 10 hospitals in the world) has signed a Letter of Intent to conduct a clinical trial with Healables to treat Fibromyalgia.
The wellness market is estimated at $6.06 Trillion [2][9] covering things like public health, personalized medicine, mental wellness, and more.
Go-to-Market Strategy: Healables ElectroGear wellness product will target sales towards physiotherapists and personal trainers in a B2B approach.
$1B: Serviceable Obtainable Market (SOM) & Earlyvangelists (EVG) — The Big Opportunity: The Serviceable Obtainable Market or Share of Market (SOM), represents the portion of the SAM that can be realistically captured and served. Earlyvangelist is a concept that mixes, “early” and “evangelist,” and means early adopter of a product or service.
A $1B SOM & EVG represents about 0.67% of the $150 billion wellness market and 0.18% of the $536 billion [19] medical device market in 2023.
Medical market
Statistically, a company that captures one tenth of one percent of a Trillion Dollar market will be a billion dollar company.
Total Goal $4,800,000
Next goal
Total Raised $156,250
First Goal
First Goal Investors are CrowdFunding (CF) investors within the first $25,000 raised.
What you get:
$250 = 130 shares
Legend Investors
Legend Investors are CrowdFunding (CF) investors within the first $500,000 raised.
What you get:
$250 = 130 shares
Superstar investors
Superstar Investors are CrowdFunding (CF) investors within the next $1,000,000 raised.
What you get:
$250 = 110 shares
Champion investors
Champion Investors are CrowdFunding (CF) investors within the next $3,300,000 raised.
What you get:
$250 = 100 shares
Reg CF investors also receive exclusive membership in the Healables CF Investor Club when they invest a minimum of $250. CF Investor Club Members will be sent special offers providing them the right to purchase exclusive merchandise according to the investor’s level of investment. Specifically:
At the 3 star level
At the 4 star level
At the 5 star level
Don’t miss out on your chance to make a difference.
1 = Science Daily, 100 million Americans live with chronic pain, but treatment research is insufficient, Indiana University, Jan. 13, 2015, Science Daily, https://www.sciencedaily.com/releases/2015/01/150113121206.htm
2 = Prescient & Strategic Intelligence, Chronic Pain Treatment Market Research Report https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market
3 = World’s Best Hospitals 2021, Newsweek, https://www.newsweek.com/best-hospitals-2021/israel
4 = Statista, Wellness 2020 market $4.4T, https://www.statista.com/topics/1336/wellness-and-spa/#topicOverview
5 = The Global Burden Of Chronic Pain, Tracy P. Jackson, M.D.; Victoria Sutton Stabile, B.A.; K.A. Kelly McQueen, M.D., M.P.H. ASA Newsletter June 2014, Vol. 78, 24–27. https://pubs.asahq.org/monitor/article-abstract/78/6/24/3059/The-Global-Burden-Of-Chronic-Pain?redirectedFrom=fulltext
5a = Chronic Pain Among Adults — United States, 2019–2021, S. Michaela Rikard, PhD1; Andrea E. Strahan, PhD1; Kristine M. Schmit, MD1; Gery P. Guy Jr., PhD1, April 14, 2023, CDC, https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm#:~:text=Discussion,%25%20in%202016%20(5)
6 = 31 Chronic Pain Statistics: US & Global Prevalence, LAURA SMITH, Associate Editorial Manager, https://www.thegoodbody.com/chronic-pain-statistics/
6a = Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., New England Journal of Medicine (NEJM), https://www.nejm.org/doi/full/10.1056/NEJMp2211040
6b = CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639433/
6c = NOPAIN Act, Voices For Non Opioid Choices, https://nonopioidchoices.org/nopain-act/
6d = New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, https://pubmed.ncbi.nlm.nih.gov/28403427/
6e = Overdose Deaths Accelerating During COVID-19, Center for Disease Control and Prevention, https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
7 = Healables compendium, Dr. Shiller, Dr. Ehrenberg, Dr. Lowell, Healables internal data
7b = The Six Reasons The Fitness Industry Is Booming, Forbes, https://www.forbes.com/sites/benmidgley/2018/09/26/the-six-reasons-the-fitness-industry-is-booming/?sh=7625abaa506d
8 = Pain Management Devices Market, Grand View Research, https://www.grandviewresearch.com/industry-analysis/pain-management-devices-market
8a – Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 – 2030, https://www.grandviewresearch.com/press-release/global-connected-health-wellness-devices-market
9 = Statista, Wellness and Spa, https://www.statista.com/topics/1336/wellness-and-spa/#topicOverview
10= S.586 – NOPAIN Act, Sponsor: Sen. Capito, Shelley Moore [R-WV] (Introduced 03/04/2021), https://www.congress.gov/bill/117th-congress/senate-bill/586/text
11 = H.R.3259 – NOPAIN Act, Sponsor: Rep. Sewell, Terri A. [D-AL-7] (Introduced 05/14/2021), https://www.congress.gov/bill/117th-congress/house-bill/3259/text?format=txt
12 = IN CASE YOU MISSED IT:CAPITO’S NO PAIN ACT TO ADDRESS OPIOID CRISIS SIGNED INTO LAW, U.S. Senator Shelley Moore Capito (R-W.Va.), https://www.capito.senate.gov/news/press-releases/in-case-you-missed-itcapitos-no-pain-act-to-address-opioid-crisis-signed-into-law
12b = Sports Medicine Market Size to Reach USD 10270 Million by 2027 at a CAGR of 7.5% | Valuates Reports PR Newswire, https://www.prnewswire.com/news-releases/sports-medicine-market-size-to-reach-usd-10270-million-by-2027-at-a-cagr-of-7-5–valuates-reports-301388619.html
13 = Statista, Medical Technology, https://www.statista.com/outlook/hmo/medical-technology/worldwide#
14 = Health and Economic Costs of Chronic Diseases, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, March 23, 2023, https://www.cdc.gov/chronicdisease/about/costs/index.htm
15 = Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 – 2030, https://www.grandviewresearch.com/press-release/global-connected-health-wellness-devices-market
16 = Physiotherapy Equipment Market Size, Share & Trends Analysis Report By Application (Neurology, Musculoskeletal, Pediatrics), By Type, By Demographics, By End Use, By Region, And Segment Forecasts, 2023 – 2030, Grand View Research, Report ID: 978-1-68038-476-5, https://www.grandviewresearch.com/industry-analysis/physiotherapy-equipment-market
17 = Emergence Research: “The global pain relief market size was USD $79.68B in 2021 and is expected to register a revenue CAGR of 4.5% during the forecast period” so that in 2023 the projected market size is USD $87B. https://www.emergenresearch.com/industry-report/pain-relief-market#:~:text=The%20global%20pain%20relief%20market,4.5%25%20during%20the%20forecast%20period
18 = Personal Fitness Trainer Market Outlook (2022 to 2032), Future Market Insights, https://www.futuremarketinsights.com/reports/personal-fitness-trainer-market
19 = Medical Devices Market Size, Fortune Business Insights, https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085
20 = Pain Medicine, South Rampart Pharma, 2022, “Significant Unmet Need & Market Opportunity” https://southrampartpharma.com/pain-medicine/
21 = Pain Management Therapeutics Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, and Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, and Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, and Hospital Pharmacy) – Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2022 – 2030, Precedence Research: The global pain management therapeutics market was valued at USD 72.41 billion in 2021 and is predicted to hit over USD 105.77 billion by 2030, expanding growth at a CAGR of 4.3% during the forecast period 2022 to 2030. https://www.precedenceresearch.com/pain-management-therapeutics-market
22 = Citation that the CE mark is globally considered the gold standard: https://insights.titansolutions.ie/en/top-benefits-of-ce-certification-for-manufacturers#:~:text=A%20product’s%20CE%20marking%20is,and%20safety%20norms%20and%20laws.
23 = The diabetic neuropathy market was valued at $3.9B in 2022, and is projected to be $6.6B in 2030. https://www.databridgemarketresearch.com/reports/global-diabetic-neuropathy-market
24 = The global market for Osteoarthritis Therapeutics estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$15.8 Billion by 2030, growing at a CAGR of 9.1% over the period 2022-2030. Knee, one of the segments analyzed in the report, is projected to record 10.1% CAGR and reach US$7.1 Billion by the end of the analysis period. https://finance.yahoo.com/news/global-osteoarthritis-therapeutics-market-reach-230800142.html#:~:text=In
25 = Fibromyalgia Treatment Market Research | 2023-2030, June 13, 2023, MarketWatch, https://www.marketwatch.com/press-release/fibromyalgia-treatment-market-research-2023-2030-2023-06-13#:~:text=Fibromyalgia
26 = Global Chronic Lower Back Pain Treatment Market Report 2023: Increasing Government Initiatives, An Aging Population, and Growing Awareness About Pain Management Drive 4.9% Annual Growth, April 25, 2023, Source: Research and Markets, https://www.globenewswire.com/news-release/2023/04/25/2653775/28124/en/Globalof-referencing-Chronic-Lower-Back-Pain-Treatment-Market-Report-2023-Increasing-Government-Initiatives-An-Aging-Population-and-Growing-Awareness-About-Pain-Management-Drive-4-9-Annual-Growt.html
27 = Physiotherapy Equipment Market Size – By Type (Equipment, Accessories), By Application (Neurology, Musculoskeletal, Cardiovascular & Pulmonary), By End-use (Hospitals & Clinics, Rehabilitation Centers, Homecare Settings), 2023 – 2032,
https://www.gminsights.com/industry-analysis/physiotherapy-equipment-market#:~:text=Physiotherapy%20Equipment%20Market%20size%20was,population%2C%20and%20advancements%20in%20technology.
28 = Data from Dr. Michael April, which was also presented at the E-Textiles 2023 Conference, November 2023, Ghent University, Ghent, Belgium, https://drive.google.com/file/d/1yEDp48FpuOCB2hWI6SWHlERc_7CjvIwN/view?usp=drive_link
Crowdfunding is designed to allow investors to support startups and early-growth companies that they are passionate about. This is different from helping a company raise money on Kickstarter. With Regulation CF Offerings, you aren’t buying products or merch. You are buying a piece of a company and helping it grow.
The majority of offerings are common stock, though some companies may raise capital through convertible note, debt, and revenue share.
Investors other than accredited investors are limited in the amounts they are allowed to invest in all Regulation Crowdfunding offerings (on this site and elsewhere) over the course of a 12-month period: If either of an investor’s annual income or net worth is less than $124,000, then the investor’s investment limit $2,500, or 5 percent of the greater of the investor’s annual income or net worth, whichever is greater. If both an investor’s annual income and net worth are $124,000 or higher, then the investor’s limit is 10 percent of the greater of their annual income or net worth, or $124,000 whichever is greater. Accredited investors are not limited in the amount they can invest.
Calculating net worth involves adding up all your assets and subtracting all your liabilities. The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest. Currently however, Canadian citizens are not able to invest in Regulation CF offerings.
Ref CF Offerings are high risk opportunities and may not retain their value. Investing in startups and small businesses is inherently risky and standard company risk factors such as execution and strategy risk are often magnified at the early stages of a company. In the event that a company goes out of business, your ownership interest could lose all value. Furthermore, private investments in startup companies are illiquid instruments that typically take up to five and seven years (if ever) before an exit via acquisition, IPO, etc.
Companies conducting a Reg CF are privately held companies, and their shares are not traded on a public stock exchange. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically receive a return on your investment under the following two scenarios: The company gets acquired by another company. The company goes public (makes an initial public offering on the NASDAQ, NYSE, or another exchange). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on the exchange. It can take 5-7 years (or longer) to see a distribution or trading, as it takes years to build companies. In many cases, there will not be any return as a result of business failure. Dalmore Group, LLC does not make investment recommendations, and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform. Investments in private placements and start-up investments in particular are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development, and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors on Regulation CF offerings will receive securities that are subject to holding period requirements. The most sensible investment strategy for start-up investing may include a balanced portfolio of different start-ups. Start-ups should only be part of your overall investment portfolio. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.
Shares sold via Regulation Crowdfunding offerings have a one-year lock up period before those shares can be sold freely. Exceptions to limitations on selling shares during the one-year lock up are transfers:
The organization of the company Dalmore Group, LLC requires information that shows the issuer company has taken steps necessary to organize as a corporation or LLC in its state of organization, is in good standing, and that the securities being issued will be duly authorized and validly issued. The corporate structure and ownership Dalmore Group, LLC works with the issuer company to disclose its organizational structure, affiliated entities, and current capitalization. The people behind the company Dalmore Group, LLC helps the issuer company disclose who is behind the operations and strategy of the company, along with their previous related experience, and Bad Actor Reports to provide evidence that the company is not disqualified from proceeding with its offering. Information provided to investors Dalmore Group, LLC checks that the issuer company is providing clear disclosure of its financial situation, business origins, and operations, and legal authority to engage in its business activities. Investor information and terms of the offering Dalmore Group, LLC reviews for consistency each instance where the issuer company describes the offering terms, and identifies to investors how the issuer company reached its current valuation and will track and keep in touch with its security holders. Review of transaction documents Dalmore Group, LLC performs an independent review of transaction documents to check for red flags & conformance with stated terms. Business due diligence Dalmore Group, LLC conducts research and due diligence on each company before it is able to accept investments on the platform. Dalmore Group, LLC will typically conduct over 30-40 hours of due diligence per opportunity, which requires the satisfactory completion of a detailed set of individual questions and data requests. Particular focus is paid to the following issues throughout the due diligence process: Problem or inefficiency being addressed Product / service overview, stage of development and anticipated milestones Demonstrated traction (e.g. revenue, pre-sales, purchase orders, signed contracts, media coverage, awards, etc.) Data to support claims made in marketing materials (e.g. user / customer metrics, signed contracts and agreements, product demonstrations, etc.) Growth strategy Employees and advisors (including ownership structure) Addressable market (e.g. size, growth, penetration, etc.) Competitive landscape and industry dynamics Exit opportunities Intellectual property Historical financials Financial projections (including error-checking, evaluation of key assumptions and reconciliation to stated growth plan) Reference checks (e.g. previous investors, advisors, etc.) Investment overview (including determination of key terms, uses of funds, and current and previous investors) The findings of the foregoing review are presented to Dalmore Group, LLC, which may approve, reject, or require additional information for the offering. Upon approval and following the onboarding process, an offering can begin accepting investments online. General considerations Notwithstanding the foregoing, these investments are illiquid, risky and speculative and you may lose your entire investment. The foregoing summarizes our standard process. However, each diligence review is tailored to the nature of the company, so the aforementioned process is not the same for every issuer. Completing the vetting process does NOT guarantee that the company has no outstanding issues or that problems will not arise in the future. While the foregoing process is designed to identify material issues, there is no guarantee that there will not be errors, omissions, or oversights in the due diligence process or in the work of third-party vendors utilized by Dalmore Group, LLC. Each investor must conduct their own independent review of documentation and perform their own independent due diligence and should ask for any further information required to make an investment decision.
If a company does not reach their minimum funding goal, all funds will be returned to the investors after the closing of their offering.
All available financial information can be found on the offering pages for the company’s Regulation Crowdfunding offering.
You may cancel your investment at any time, for any reason until 48 hours prior to a closing occurring. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: cfsupport@healables.com
Please download additional Education Materials here
of a $4,800,000 goal
Pre-Market Valuation: $29.27M
If you invest, you’re betting Healables will be worth more in the future.
Dr. George Lowell, Retired U.S. Army Colonel, BioTech Investor, Board Member, BiondVax, Former Chief Scientific Officer for BioDefense at GSK Biologicals, Early Seed Investor in Healables.
Become a Healables investor.
Invested this round & previously
min $25
min $25
min $25
Pre-Market Valuation: $29.27M
If you invest, you’re betting Healables will be worth more in the future.
Dr. George Lowell, Retired U.S. Army Colonel, BioTech Investor, Board Member, BiondVax, Former Chief Scientific Officer for BioDefense at GSK Biologicals, Early Seed Investor in Healables.
Invested this round & previously